Acute Pancreatitis in a Patient Taking Semaglutide
Femina Patel, Arnold Gan, Karen Chang, Kenneth J. Vega
Abstract
The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. Though recent evidence suggests no increased risk of acute pancreatitis (AP) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with GLP-1 RAs. We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes. As GLP-1 RA use increases, clinicians should be aware of their potential to cause acute pancreatitis.
Topics & Concepts
SemaglutideMedicineAcute pancreatitisType 2 diabetesDiabetes mellitusPancreatitisAgonistGlucagon-like peptide 1 receptorInternal medicineEndocrinologyReceptorLiraglutideDiabetes Treatment and ManagementPancreatitis Pathology and TreatmentDiabetes Management and Research